Which has higher valuation and earnings, ESPR or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Esperion Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Esperion Therapeutics $403.14M 2.01 -$22.68M -$0.06 N/A Telix Pharmaceuticals $803.79M 4.04 -$7.12M N/A N/A

Esperion Therapeutics (ESPR) Competitors

$3.15 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$3.15 0.00 (0.00%)

As of 07:57 PM Eastern

Compare

ESPR vs. TLX, DNLI, BEAM, TNGX, and RCUS

Should you buy Esperion Therapeutics stock or one of its competitors? MarketBeat compares Esperion Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Esperion Therapeutics include Telix Pharmaceuticals (TLX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Tango Therapeutics (TNGX), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

How does Esperion Therapeutics compare to Telix Pharmaceuticals?

Esperion Therapeutics (NASDAQ:ESPR) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Esperion Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than Esperion Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.01	-$22.68M	-$0.06	N/A
Telix Pharmaceuticals	$803.79M	4.04	-$7.12M	N/A	N/A

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Esperion Therapeutics. MarketBeat recorded 2 mentions for Telix Pharmaceuticals and 1 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 1.89 beat Telix Pharmaceuticals' score of 1.50 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Esperion Therapeutics	Very Positive
Telix Pharmaceuticals	Very Positive

Esperion Therapeutics currently has a consensus target price of $5.54, suggesting a potential upside of 75.87%. Telix Pharmaceuticals has a consensus target price of $21.13, suggesting a potential upside of 120.97%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Esperion Therapeutics has a net margin of 0.12% compared to Telix Pharmaceuticals' net margin of 0.00%. Telix Pharmaceuticals' return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Telix Pharmaceuticals	N/A	N/A	N/A

47.4% of Esperion Therapeutics shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Telix Pharmaceuticals beats Esperion Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Esperion Therapeutics compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Esperion Therapeutics (NASDAQ:ESPR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Denali Therapeutics and Denali Therapeutics both had 1 articles in the media. Esperion Therapeutics' average media sentiment score of 1.89 beat Denali Therapeutics' score of 0.93 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Denali Therapeutics	Positive
Esperion Therapeutics	Very Positive

Denali Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Esperion Therapeutics has higher revenue and earnings than Denali Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	10.40	-$512.54M	-$2.88	N/A
Esperion Therapeutics	$403.14M	2.01	-$22.68M	-$0.06	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Denali Therapeutics' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Denali Therapeutics currently has a consensus price target of $34.25, indicating a potential upside of 58.13%. Esperion Therapeutics has a consensus price target of $5.54, indicating a potential upside of 75.87%. Given Esperion Therapeutics' higher probable upside, analysts plainly believe Esperion Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Esperion Therapeutics beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Esperion Therapeutics compare to Beam Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Esperion Therapeutics currently has a consensus target price of $5.54, indicating a potential upside of 75.87%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 61.33%. Given Esperion Therapeutics' higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Esperion Therapeutics has higher revenue and earnings than Beam Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.01	-$22.68M	-$0.06	N/A
Beam Therapeutics	$139.74M	21.37	-$79.99M	-$0.68	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Beam Therapeutics' net margin of -39.66%. Esperion Therapeutics' return on equity of -0.14% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Esperion Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

In the previous week, Beam Therapeutics had 4 more articles in the media than Esperion Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 1 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 1.89 beat Beam Therapeutics' score of 1.08 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Esperion Therapeutics	Very Positive
Beam Therapeutics	Positive

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Beam Therapeutics beats Esperion Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Esperion Therapeutics compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Esperion Therapeutics (NASDAQ:ESPR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Tango Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Esperion Therapeutics has a net margin of 0.12% compared to Tango Therapeutics' net margin of -151.15%. Esperion Therapeutics' return on equity of -0.14% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Esperion Therapeutics has higher revenue and earnings than Tango Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	71.75	-$101.59M	-$0.83	N/A
Esperion Therapeutics	$403.14M	2.01	-$22.68M	-$0.06	N/A

Tango Therapeutics currently has a consensus price target of $38.42, suggesting a potential upside of 24.17%. Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 75.87%. Given Esperion Therapeutics' higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Tango Therapeutics had 22 more articles in the media than Esperion Therapeutics. MarketBeat recorded 23 mentions for Tango Therapeutics and 1 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 1.89 beat Tango Therapeutics' score of 0.13 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tango Therapeutics	Neutral
Esperion Therapeutics	Very Positive

Summary

Tango Therapeutics and Esperion Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Esperion Therapeutics compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Esperion Therapeutics (NASDAQ:ESPR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Esperion Therapeutics has a net margin of 0.12% compared to Arcus Biosciences' net margin of -156.36%. Esperion Therapeutics' return on equity of -0.14% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Esperion Therapeutics has higher revenue and earnings than Arcus Biosciences. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.14	-$353M	-$3.18	N/A
Esperion Therapeutics	$403.14M	2.01	-$22.68M	-$0.06	N/A

Arcus Biosciences has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Arcus Biosciences currently has a consensus price target of $35.10, suggesting a potential upside of 47.17%. Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 75.87%. Given Esperion Therapeutics' higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Arcus Biosciences had 21 more articles in the media than Esperion Therapeutics. MarketBeat recorded 22 mentions for Arcus Biosciences and 1 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 1.89 beat Arcus Biosciences' score of 1.00 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Arcus Biosciences	Positive
Esperion Therapeutics	Very Positive

Summary

Esperion Therapeutics beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks.

Get Esperion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESPR vs. The Competition

Export

Metric	Esperion Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$811.73M	$2.99B	$6.75B	$12.02B
Dividend Yield	N/A	1.76%	2.66%	5.61%
P/E Ratio	-52.50	18.07	24.04	24.43
Price / Sales	2.01	302.43	510.75	109.73
Price / Cash	N/A	56.52	44.01	55.64
Price / Book	-2.50	3.99	10.66	6.79
Net Income	-$22.68M	$75.85M	$3.56B	$337.66M
7 Day Performance	0.64%	1.07%	0.05%	2.08%
1 Month Performance	0.64%	-3.27%	0.37%	3.16%
1 Year Performance	162.50%	20.00%	22.73%	27.78%

Esperion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESPR Esperion Therapeutics	4.3241 of 5 stars	$3.15 flat	$5.54 +75.9%	+160.3%	$811.73M	$403.14M	N/A	200
TLX Telix Pharmaceuticals	4.4834 of 5 stars	$9.22 -0.9%	$21.13 +129.1%	-44.5%	$3.16B	$803.79M	N/A	1,184
DNLI Denali Therapeutics	3.2249 of 5 stars	$19.54 +0.1%	$34.25 +75.3%	+38.4%	$3.10B	$330.53M	N/A	430
BEAM Beam Therapeutics	3.0518 of 5 stars	$29.78 +1.3%	$46.83 +57.3%	+64.4%	$3.02B	$139.74M	N/A	510	Gap Down
TNGX Tango Therapeutics	2.3879 of 5 stars	$30.93 +53.0%	$34.17 +10.5%	+529.1%	$2.92B	$62.38M	N/A	90	Analyst Forecast Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESPR) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Esperion Therapeutics (ESPR) Competitors

ESPR vs. TLX, DNLI, BEAM, TNGX, and RCUS

How does Esperion Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Esperion Therapeutics compare to Denali Therapeutics?

Summary

How does Esperion Therapeutics compare to Beam Therapeutics?

Summary

How does Esperion Therapeutics compare to Tango Therapeutics?

Summary

How does Esperion Therapeutics compare to Arcus Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR vs. The Competition

Esperion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Esperion Therapeutics (ESPR) Competitors

ESPR vs. TLX, DNLI, BEAM, TNGX, and RCUS

How does Esperion Therapeutics compare to Telix Pharmaceuticals?

Which has more volatility and risk, ESPR or TLX?

Which has higher valuation and earnings, ESPR or TLX?

Does the media favor ESPR or TLX?

Do analysts recommend ESPR or TLX?

Is ESPR or TLX more profitable?

Do institutionals & insiders have more ownership in ESPR or TLX?

Summary

How does Esperion Therapeutics compare to Denali Therapeutics?

Do insiders and institutionals believe in DNLI or ESPR?

Does the media prefer DNLI or ESPR?

Which has more volatility and risk, DNLI or ESPR?

Which has preferable earnings & valuation, DNLI or ESPR?

Is DNLI or ESPR more profitable?

Do analysts rate DNLI or ESPR?

Summary

How does Esperion Therapeutics compare to Beam Therapeutics?

Do analysts rate ESPR or BEAM?

Which has higher earnings and valuation, ESPR or BEAM?

Is ESPR or BEAM more profitable?

Which has more risk & volatility, ESPR or BEAM?

Does the media refer more to ESPR or BEAM?

Do institutionals & insiders believe in ESPR or BEAM?

Summary

How does Esperion Therapeutics compare to Tango Therapeutics?

Which has more risk & volatility, TNGX or ESPR?

Is TNGX or ESPR more profitable?

Which has stronger earnings and valuation, TNGX or ESPR?

Do analysts prefer TNGX or ESPR?

Do insiders & institutionals have more ownership in TNGX or ESPR?

Does the media prefer TNGX or ESPR?

Summary

How does Esperion Therapeutics compare to Arcus Biosciences?

Is RCUS or ESPR more profitable?

Which has higher earnings & valuation, RCUS or ESPR?

Which has more risk and volatility, RCUS or ESPR?

Do analysts prefer RCUS or ESPR?

Do institutionals & insiders have more ownership in RCUS or ESPR?

Does the media prefer RCUS or ESPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR vs. The Competition

Esperion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools